Search results
30 wrz 2021 · The mainstay of treatment for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) is either surgery followed by adjuvant radiation therapy or definitive concurrent chemoradiation (CRT) reserving surgery as salvage therapy, referred to as the organ-preservation approach.
What are the Side Effects of Treatment? Surgery for head and neck cancers often changes the patient’s ability to chew, swallow, or talk. The patient may look different after surgery, and the face and neck may be swollen. The swelling usually goes away within a few weeks.
13 cze 2021 · Head and neck squamous cell carcinoma (HNSCC) ranks sixth among the most common cancers, accounting for approximately 3.3% of all cancer cases. While HNSCC was generally treated with postoperative concurrent chemo-radiotherapy, traditional chemotherapy agents often lead to multiple side effects.
16 maj 2013 · Locally advanced disease includes advanced T stage (T3 and T4) and advanced neck disease (N2 or greater). In an era of nonsurgical organ preservation approaches, primary and salvage surgery remains an important option in the management of primary head and neck malignancies.
Treatment of locally advanced head and neck squamous cell carcinomas requires a multidisciplinary approach to be able to offer patients definitive therapy while aiming to preserve organ function and minimize acute and long-term toxicities.
29 kwi 2022 · Patients with PD-L1–expressing metastatic head and neck squamous cell carcinoma should be treated with pembrolizumab or the combination of pembrolizumab and chemotherapy in the first line.
8 maj 2024 · The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is 6 to 15 months depending on patient- and disease-related factors.
